| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Irinotecan | FIMM | pan-cancer | AAC | -0.0093 | 0.9 |
| mRNA | MK 1775 | CTRPv2 | pan-cancer | AAC | 0.0025 | 0.9 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | AEW541 | CCLE | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | Vorinostat | gCSI | pan-cancer | AAC | 0.0034 | 0.9 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | 0.003 | 0.9 |
| mRNA | PD 153035 | CTRPv2 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | 0.003 | 0.9 |